US-based health care performance improvement company Vizient has entered into an agreement to acquire Intalere from Intermountain Healthcare.
The latest move will allow the company to expand its capabilities in the health care supply chain.
Go deeper with GlobalData
As part of the agreement, Intermountain Healthcare and Vizient will collaborate for supply chain solutions and services and further expand their existing relationship with Vizient in clinical as well as cost analytics.
Vizient president and CEO Byron Jobe said: “This acquisition builds on the strengths of both Vizient and Intalere and furthers our ability to meet the growing needs of the increasingly diverse range of members and customers we serve.”
With the planned acquisition of Intalere, Vizient will be able to align cost, quality and market performance and support its mission to strengthen members’ delivery of high value care.
The company can align its performance by reinforcing its commitment to supply chain as a strategic asset for health care providers and by expanding its non-acute footprint to create additional opportunities through Provista, its subsidiary.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIntermountain Healthcare chief financial officer and executive vice-president Bert Zimmerli said: “Intermountain Healthcare looks forward to continuing to work together with Vizient in our common goal of providing patients access to high-quality care at the most affordable cost.
“This aligns very well with our aspiration of executing a population health strategy by providing value-based care and services to an increased number of patients, families, and communities.”
The transaction is subject to standard regulatory review and is expected to close during the first quarter of next year.
The companies have not disclosed the transaction value.
